KRAS and lung cancer: Some studies have shown that CDK4 and cyclin D1 expression is correlated with the presence of KRAS mutation in lung tumors (15), and a synthetic lethal interaction occurs between KRAS and CDK4 in lung cancer tumor progression (16, 17).